nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-4B17C465·Framework v5.13·Pipeline v0.4·Evaluated 13 Nov 2026·OECD: 3.1 Basic medicine·Subfield: Obstetrics and Gynecology·Basis: Full text·Type: Laboratory experiment

Maternal Angiotensin Increases Placental Leptin in Early Gestation via an Alternative Renin-Angiotensin System Pathway: Suggesting a Link to Preeclampsia

Olivia Nonn et al.Olivia Nonn, Cornelius Fischer, Sabrina Geisberger et al.·2021·Hypertension·10.1161/hypertensionaha.120.16425 ↗

Primary claim

Ang IV decreases trophoblastic mitochondrial respiration and increases placental leptin via placental LNPEP.

Tentative · Ang IV-induced leptin and LNPEP dependence were not directly tested
In brief

Placental receptor mapping and paired peptide measurements advance pregnancy RAS biology, but the proposed Ang IV–LNPEP–leptin mechanism remains untested at its decisive links.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Unlikely to hold — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Various studies found an association of different renin-angiotensin system (RAS) components with gestational duration and preterm birth, as well as with preeclampsia. Approximately 25% of first-time pregnant women develop a mild to severe hypertension in pregnancy or even preeclampsia. Based on recently published single-cell RNA-sequencing, we hypothesized an alternative RAS function in placenta and furthermore, an implication in hypertensive disorders in pregnancy. Placental RAS expression and localization was analyzed via quantitative polymerase chain reaction and in situ mRNA padlock probes. Tissue was collected from first-trimester elective termination (n=198), from healthy third-trimester controls (n=54), from early-onset preeclamptic (n=54) and age-matched controls (n=29), as well as first-trimester placentae from women with a high uterine artery resistance index (high-risk for preeclampsia, n=9) and controls (n=8). Serum levels of Ang (angiotensin) I to IV from women before and after conception were measured via mass spectrometry (n=10). Placental explants were cultured in 2.5% oxygen with Ang II, candesartan, and leptin. Seahorse XF96 MitoStress assays assessed trophoblast metabolism. Here, we show that maternal angiotensin acts on placental LNPEP (leucine aminopeptidase), that is, angiotensin IV-receptor and fetal angiotensin on placental AGTR1 (angiotensin II receptor type 1). Maternal circulating RAS shifts towards Ang IV in pregnancy. Ang IV decreases trophoblastic mitochondrial respiration and increases placental leptin via placental LNPEP. Lower placental LNPEP in preeclampsia and in first-trimester patients at high-risk for preeclampsia suggests a new alternative route in maternal RAS signaling and may contribute to hypertension and disease in pregnancy. The study shows how hypertensive disorders in pregnancy may be connected metabolic alterations that finally seem to contribute to the multifactorial disease in pregnancy, preeclampsia.

Key Claims

Primary finding · Tentative

Ang IV decreases trophoblastic mitochondrial respiration and increases placental leptin via placental LNPEP.

Unlikely to hold — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

Ang IV-induced leptin and LNPEP dependence were not directly tested

Abstract
Quote verified
Secondary · Supported

serum Ang III (mean±SEM, 2.6±0.6 pmol/L) and Ang IV (mean±SEM, 4.6±1.0 pmol/L), the 2 peptide hormones resulting from Ang I and Ang II, were significantly increased in pregnancy

paired equilibrium measurements support increases in 10 ART patients without isolating pregnancy from treatment-associated changes

Results, Serum Ang IV Increases in Pregnancy, Figure 2E
Quote verified
Secondary · Tentative

Lower placental LNPEP in preeclampsia and in first-trimester patients at high-risk for preeclampsia suggests a new alternative route in maternal RAS signaling and may contribute to hypertension and disease in pregnancy.

observational group differences with gestational-age confounding and risk classification do not establish a contribution to disease

Abstract; Fig. 5
Quote verified
Secondary · Tentative

Leptin downregulates placental LNPEP.

small first-trimester explant experiments with conflicting treatment doses limit the unqualified claim

Novelty and Significance, What Is New
Quote verified
Secondary · Supported

The cell cluster annotated as syncytiotrophoblast expressed LNPEP as the only Ang receptor, whereas AGTR1 was exclusively expressed in cells annotated as fibroblasts.

single-cell expression patterns are corroborated by spatial localization methods

Results, Maternal and Fetal Angs Have Different Target Placental RAS Receptors, Figure 1
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Complementary methods resolve placental receptor localization

Single-cell expression analysis, in situ padlock probes, and immunofluorescence distinguish syncytiotrophoblast LNPEP from AGTR1 around fetal vessels, addressing conflicting earlier localization reports.

↳ Results, Figure 1; Discussion, opening paragraph

#methodological rigour

Paired sampling tracks early pregnancy peptides

Mass spectrometry compares Ang I–IV within the same 10 women before conception and around week 7, showing increased Ang III and Ang IV in the studied ART cohort.

↳ Methods, Serum Ang Measurement; Results, Figure 2E

#positioning

Clinical associations receive explicit confounder checking

Reduced LNPEP is reported in two independently recruited preeclampsia cohorts and an early high-risk group. The Discussion explicitly investigates labor and preterm-delivery effects using an independent single-cell dataset.

↳ Results, Figure 5A–B; Discussion, gestational-age analysis

Limitations

#methodological rigour

Headline pathway exceeds direct experimental tests

The abstract attributes leptin induction to Ang IV acting through LNPEP, but Figure 4 measures induction after Ang II and does not directly manipulate LNPEP. The complete pathway therefore remains a hypothesis rather than an identified mechanism.

↳ Abstract; Results, Figures 3–4

#methodological rigour

Metabolic assays omit independent replicate definitions

Figure 3 reports metabolic effects and statistical tests without specifying sample sizes or whether replication represents independent experiments or wells. Explant reporting also leaves donor-versus-tissue replication unclear.

↳ Methods, Seahorse XF Experiments and Placental Explants; Figures 3–4 legends

#reporting

Treatment concentrations and cohort counts conflict

Methods and Figure 4 disagree on candesartan dosing, 0.1 versus 1 μmol/L, and leptin dosing, 100 versus 10 ng/mL. The high-risk groups total 17 in the abstract versus 16 in Figure 5B, and preeclampsia cohort counts also vary across sections.

↳ Abstract; Methods, Sample Collection and Placental Explants; Discussion; Figures 4–5 legends

Does this match your read? Add your assessment ↓

Nabu Commentary

The clearest advances are the spatial separation of placental RAS receptors, paired angiotensin measurements, and reduced LNPEP expression across the studied pregnancy groups. Figures 3–4 support individual metabolic and leptin responses, but neither direct LNPEP dependence nor Ang IV-induced leptin is established. That distinction limits both mechanistic execution and the precision of the abstract's conclusion. The Discussion engages competing localization reports and investigates clinical confounding, although residual gestational-age differences remain. Unclear replication and conflicting concentrations and cohort counts further constrain interpretation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.1±0.2

Contribution
3.7

Cell-type receptor localization, paired angiotensin measurements, and reduced LNPEP across clinical cohorts meaningfully extend placental RAS observations. The proposed mechanistic extension remains less established than these descriptive findings.

Results, Figures 1, 2E, and 5
Methodological Rigour
2.7

Complementary localization, serum, and cohort approaches support the descriptive findings, but direct LNPEP-dependence tests and Ang IV-induced leptin measurements are absent. Unstated metabolic-assay replicate units and conflicting treatment concentrations further limit interpretation.

Methods, Placental Explants and Seahorse XF Experiments; Figures 3–4
Reporting
2.9

The experimental sequence is followable, but the headline presents an inferred pathway as demonstrated. Conflicting concentrations and cohort counts also reduce reporting precision.

Abstract; Methods, Sample Collection and Placental Explants; Figures 4–5 legends
Positioning
3.6

The Discussion directly engages conflicting receptor-localization literature and investigates labor and preterm-delivery confounding using an independent dataset. This engagement does not fully resolve gestational-age confounding or trace the limitations of the BeWo model and indirect LNPEP inference.

Discussion, receptor-localization comparison, gestational-age analysis, and fetal AGT limitation

Reliability

Caveats4 of 4 checks


Results checkNoted
  • Ang IV decreases trophoblastic mitochondrial respiration and increases placental leptin via placental LNPEP: "Candesartan was used in its active form (Selleckchem, Munich, Germany) at a concentration of 0.1 μmol/L" (Methods, Placental Explants) vs "AT1R (Ang II receptor type 1)-blocker candesartan (1 μmol/L)" (Figure 4C legend). The stated candesartan concentrations differ tenfold between Methods and Figure 4C. → Effect on result unclear
  • Leptin downregulates placental LNPEP: "Leptin at a concentration of 100 ng/mL (Gibco)" (Methods, Placental Explants, leptin concentration) vs "Ang II (0.1 μmol/L), Ang IV (4 nmol/L), and leptin (10 ng/mL) for 6 h" (Figure 4 legend, panel E). The stated leptin concentrations differ tenfold between Methods and Figure 4E. → Effect on result unclear
  • Lower placental LNPEP in preeclampsia and in first-trimester patients at high-risk for preeclampsia suggests a new alternative route in maternal RAS signaling and may contribute to hypertension and disease in pregnancy: "from early-onset preeclamptic (n=54) and age-matched controls (n=29)" (Abstract, cohort sizes) vs "Preeclamptic placentae and respective controls were sampled at the University Hospital of Graz, Austria (n=42) and within an independent cohort15 at the Oslo University Hospital, Norway (n=33)." (Methods, Sample Collection). The abstract gives 54+29=83 samples, whereas the Methods give 42+33=75 across Graz and Oslo. → Effect on result unclear
  • Lower placental LNPEP in preeclampsia and in first-trimester patients at high-risk for preeclampsia suggests a new alternative route in maternal RAS signaling and may contribute to hypertension and disease in pregnancy: "Graz cohort: 253.8±4.1 days (n=27) controls and 236.9±3.5 days (n=37) preeclamptic pregnancies" (Discussion, gestational age paragraph) vs "Preeclamptic placentae and respective controls were sampled at the University Hospital of Graz, Austria (n=42)" (Methods, Sample Collection). The Discussion's Graz groups sum to 27+37=64, whereas Methods reports Graz n=42. → Effect on result unclear
  • Lower placental LNPEP in preeclampsia and in first-trimester patients at high-risk for preeclampsia suggests a new alternative route in maternal RAS signaling and may contribute to hypertension and disease in pregnancy: "(high-risk for preeclampsia, n=9) and controls (n=8)" (Abstract, high-risk cohort) vs "indicating high-risk for PE (n=16; Mann-Whitney U test, P<0.05)" (Figure 5 legend, panel B). The abstract's groups sum to 9+8=17, whereas Figure 5B reports n=16. → Effect on result unclear
Reporting and transparencyClean

Written consent and local ethics approval are declared, disclosures state none, and data are available upon reasonable request. No retained finding establishes a reporting or transparency concern about research conduct.

Conflict of interest: declared · Ethics approval: declared · Data availability: declared

Reference IntegrityClean

62 references in manuscript 61 of 61 checkable references found in an index 1 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 13 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Reproductive health and childbirth · Maternal disorders
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesLarge
CitationsFWCI 5.4
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The Ang IV/LNPEP/leptin mechanism was pinned down under controlled conditions in BeWo cells and ex vivo placental explants, with only associative human cohort data.

From the paper
“Furthermore, our results indicate a new pharmacological RAS target.”

The paper names a concrete real-world use of its findings, LNPEP as a novel pharmacological target for preeclampsia, but does not name who would act on it.

Pathway

Drug developers could develop LNPEP-targeted therapies as a nonteratogenic alternative to ARBs and ACE inhibitors for hypertensive disorders in pregnancy.

Barrier

The mechanism is demonstrated only in cell lines and ex vivo explants with small observational cohorts, so in vivo causal efficacy and safety of targeting LNPEP in pregnancy remain untested.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Placental physioxia is based on spatial and temporal variations of placental oxygenation throughout pregnancy

    Berthold Huppertz · 2023 · Basic medicine

    Primary claim

    In early-onset preeclampsia cases, all in vivo data available today point to increased oxygen values in the intervillous space of the placenta.

    Tentative
    Evidence Score
    2.4±0.2
    Reliability
    Caveats
  2. Maternal platelets at the first trimester maternal-placental interface - Small players with great impact on placenta development

    Jacqueline Guettler, Désirée Forstner, Martin Gauster · 2021 · Basic medicine

    Primary claim

    In normal early human pregnancy, maternal platelets may contribute to placenta development by acting on both the extravillous- and the villous trophoblast compartment.

    Tentative
    Evidence Score
    3.1±0.1
    Reliability
    Caveats
  3. Molecular characteristics of established trophoblast-derived cell lines

    Jana Pastuschek, Olivia Nonn, Ruby N Gutiérrez-Samudio, et al. · 2021 · Basic medicine

    Primary claim

    In general, characteristics and markers of choriocarcinoma derived cell lines seem to be more similar to in vivo trophoblast than immortalized cell lines and thus might be regarded as more suitable models.

    Tentative
    Evidence Score
    3.2±0.1
    Reliability
    Caveats

How the rubric works →